Bellus Health Inc. clinical trials

Acquired by GlaxoSmithKline, Jun 28, 2023 · source ↗

The registry lists 19 studies whose lead sponsor is Bellus Health Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 19 of 19. All GlaxoSmithKline studies →

• A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughCompletedNCT05599191Phase 3

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughActive, not recruitingNCT05600777Phase 3

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of AgeCompletedNCT06222892Phase 1

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted after Bellus Health Inc. became part of GlaxoSmithKline

• Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference FormulationCompletedNCT05570539Phase 1

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and CamlipixantCompletedNCT05959447Phase 1

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted after Bellus Health Inc. became part of GlaxoSmithKline

• A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy ParticipantsCompletedNCT06497517Phase 1

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted after Bellus Health Inc. became part of GlaxoSmithKline

• Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of CamlipixantCompletedNCT05899829Phase 1

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian SubjectsCompletedNCT06179537Phase 1

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted after Bellus Health Inc. became part of GlaxoSmithKline

• A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic DermatitisCompletedNCT04693195Phase 2

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937CompletedNCT05244759Phase 1

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughCompletedNCT04678206Phase 2

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic CoughTerminatedNCT03979638Phase 2

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food EffectCompletedNCT03638180Phase 1

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II DiabetesCompletedNCT00675857Phase 2

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• European Study of 3APS in Mild to Moderate Alzheimer's Disease PatientsStatus unknownNCT00217763Phase 3

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownNCT00314912Phase 3

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownNCT00088673Phase 3

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• Study of the Safety and Efficacy of NC-503 in Secondary (AA) AmyloidosisCompletedNCT00035334Phase 2/3

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline

• Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid AngiopathyCompletedNCT00056238Phase 2

  Sponsor listed in the registry: Bellus Health Inc. - a GSK company · First submitted before Bellus Health Inc. became part of GlaxoSmithKline